The GLOVe regimen, combining glofitamab, lenalidomide, and venetoclax, shows rapid and deep responses in high-risk MCL patients with manageable toxicity. All evaluable patients achieved complete ...
Lunsumio and Polivy showed an 88% overall response rate in relapsed/refractory MCL patients, with high efficacy in high-risk subgroups. The combination therapy was well-tolerated, despite a high ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results